Imran Khan, Catherine MarElia-Bennet, Julia Lefler, Mariyam Zuberi, Eric Denbaum, Akiko Koide, Dean M Connor, Ann-Marie Broome, Thierry Pécot, Cynthia Timmers, Michael C Ostrowski, Shohei Koide, John P O'Bryan
RAS is the most frequently mutated oncogene in human cancer with nearly ~20% of cancer patients possessing mutations in one of three RAS genes ( K, N or HRAS ). However, KRAS is mutated in nearly 90% of pancreatic ductal carcinomas (PDAC). Although pharmacological inhibition of RAS has been challenging, KRAS(G12C)-specific inhibitors have recently entered the clinic. While KRAS(G12C) is frequently expressed in lung cancers, it is rare in PDAC. Thus, more broadly efficacious RAS inhibitors are needed for treating KRAS mutant-driven cancers such as PDAC...
May 5, 2021: Small GTPases